CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Empagliflozin and metformin

Last Updated: April 4, 2016
Result type: Reports
Project Number: SR0489-000
Product Line: Reimbursement Review

Generic Name: Empagliflozin and metformin

Brand Name: Synjardy

Manufacturer: Boehringer Ingelheim (Canada) Ltd.

Therapeutic Area: Diabetes mellitus (Type 2)

Indications: Diabetes mellitus (Type 2)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 25, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions